Articles with public access mandates - Rajesh PahwaLearn more
Not available anywhere: 11
Thalamic DBS with a constant-current device in essential tremor: a controlled clinical trial
RE Wharen Jr, MS Okun, BL Guthrie, RJ Uitti, P Larson, K Foote, H Walker, ...
Parkinsonism & related disorders 40, 18-26, 2017
Mandates: US National Institutes of Health
Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel
R Pahwa, SH Isaacson, D Torres-Russotto, FB Nahab, PM Lynch, ...
Expert review of neurotherapeutics 18 (8), 669-680, 2018
Mandates: US National Institutes of Health
Dyskinesia matters
MA Cenci, S Riggare, R Pahwa, D Eidelberg, RA Hauser
Movement Disorders 35 (3), 392-396, 2020
Mandates: US National Institutes of Health, Swedish Research Council, Michael J Fox …
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients
MT Elkurd, LB Bahroo, R Pahwa
Neurodegenerative disease management 8 (2), 73-80, 2018
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin
KE Lyons, R Pahwa, N Hermanowicz, T Davis, F Pagan, S Isaacson
Expert Review of Clinical Pharmacology 12 (7), 681-691, 2019
Mandates: US National Institutes of Health
Extended-release amantadine for Levodopa-induced dyskinesia
K Dashtipour, AR Tafreshi, R Pahwa, KE Lyons
Expert Review of Neurotherapeutics 19 (4), 293-299, 2019
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
ADS-5102 (Amantadine) extended release for levodopa-induced dyskinesia
R Pahwa, RA Hauser
JAMA neurology 74 (12), 1507-1508, 2017
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease
AM Richmond, KE Lyons, R Pahwa
Expert Opinion on Drug Safety 22 (7), 563-579, 2023
Mandates: Michael J Fox Foundation, Parkinson's Foundation, USA
Amantadine: an old drug reborn
R Pahwa
The Lancet Neurology 20 (12), 975-977, 2021
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Unmet needs in the diagnosis and treatment of Parkinson’s disease psychosis and dementia-related psychosis
M Sabbagh, GW Small, SH Isaacson, Y Torres-Yaghi, F Pagan, R Pahwa
International journal of psychiatry in clinical practice 27 (1), 69-81, 2023
Mandates: Parkinson's Foundation, USA
Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease
JC Rothlind, MK York, P Luo, K Carlson, WJ Marks Jr, FM Weaver, ...
Parkinsonism & Related Disorders 95, 23-27, 2022
Mandates: US National Institutes of Health, US Department of Veterans Affairs, Michael …
Available somewhere: 99
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results
CG Goetz, BC Tilley, SR Shaftman, GT Stebbins, S Fahn, ...
Movement disorders: official journal of the Movement Disorder Society 23 (15 …, 2008
Mandates: US National Institutes of Health
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial
FM Weaver, K Follett, M Stern, K Hur, C Harris, WJ Marks, J Rothlind, ...
Jama 301 (1), 63-73, 2009
Mandates: US National Institutes of Health
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease
KA Follett, FM Weaver, M Stern, K Hur, CL Harris, P Luo, WJ Marks Jr, ...
New England Journal of Medicine 362 (22), 2077-2091, 2010
Mandates: US National Institutes of Health
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues
JM Bronstein, M Tagliati, RL Alterman, AM Lozano, J Volkmann, A Stefani, ...
Archives of neurology 68 (2), 165-165, 2011
Mandates: US National Institutes of Health
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
GU Höglinger, NM Melhem, DW Dickson, PMA Sleiman, LS Wang, L Klei, ...
Nature genetics 43 (7), 699-705, 2011
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, Canadian …
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
D Weintraub, S Hoops, JA Shea, KE Lyons, R Pahwa, ...
Movement disorders: official journal of the Movement Disorder Society 24 (10 …, 2009
Mandates: US National Institutes of Health
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes
FM Weaver, KA Follett, M Stern, P Luo, CL Harris, K Hur, WJ Marks Jr, ...
Neurology 79 (1), 55-65, 2012
Mandates: US National Institutes of Health
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit
MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ...
JAMA neurology 71 (5), 543-552, 2014
Mandates: US National Institutes of Health, Parkinson's Foundation, USA
Understanding verbal fluency in healthy aging, Alzheimer's disease, and Parkinson's disease.
J McDowd, L Hoffman, E Rozek, KE Lyons, R Pahwa, J Burns, S Kemper
Neuropsychology 25 (2), 210, 2011
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program